As we reach the midpoint of 2026, MetaSafe is proud to reflect on a highly productive first half of the year. During the past six months, we have successfully delivered several critical metabolite identification (Met-ID) studies supporting pharmaceutical development programs across a range of therapeutic areas.
Among the highlights were projects involving the detection and characterization of unusual and previously unreported drug metabolites. Such findings are often crucial for understanding metabolic pathways, supporting safety assessments, and addressing regulatory expectations related to human metabolites and MIST evaluations.
The increasing complexity of modern drug candidates continues to drive demand for advanced analytical approaches and scientific interpretation. MetaSafe has worked closely with sponsor teams to provide rapid and reliable metabolite profiling, structural elucidation, and project-specific scientific guidance.
We are grateful for the trust our clients place in us and for the dedication of our scientific team. Looking ahead, we remain focused on delivering high-quality metabolism studies that help pharmaceutical companies make informed development decisions and navigate increasingly complex regulatory landscapes.